Mohammed Milhem: Clinical Trials

6 trials sponsored by Mohammed Milhem, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 recruiting. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 4, Active not recruiting 1, Recruiting 1
Phase 22Completed 2

Follow Mohammed Milhem: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
5 Azacytidine, Pembrolizumab, Nivolumab - Solid Tumor, Locally Advanced Solid Tumor
Phase 1RecruitingMohammed Milhem352026-02-112026-05-28
Chlorpromazine and Standard of Care in Glioblastoma
Chlorpromazine, Temozolomide, Radiation Therapy - Glioblastoma Multiforme
Phase 1CompletedMohammed Milhem102022-01-282025-09-02
High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
Ascorbate - Soft Tissue Sarcoma
Phase 1 / Phase 2CompletedMohammed Milhem252019-06-272026-06-18
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Zoledronic Acid - Chondrosarcoma
Phase 1Active not recruitingMohammed Milhem172017-07-182025-11-06
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
Decitabine, Gemcitabine - Pancreatic Ductal Adenocarcinoma, Sarcoma
Phase 1CompletedMohammed Milhem362016-12-052023-07-28
SLM + Axitinib for Clear Cell RCC
Selenomethionine (SLM), Axitinib - Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Phase 1 / Phase 2CompletedMohammed Milhem452016-01-012026-05-06

Conditions studied

Sarcoma (2)  ·  Chondrosarcoma (1)  ·  Glioblastoma (1)  ·  Kidney Neoplasms (1)  ·  Neoplasm Metastasis (1)

Interventions

Ascorbic Acid (1)  ·  Axitinib (1)  ·  Azacitidine (1)  ·  Chlorpromazine (1)  ·  Decitabine (1)  ·  Gemcitabine (1)  ·  Nivolumab (1)  ·  Radiotherapy (1)  ·  Selenomethionine (1)  ·  Temozolomide (1)  ·  Zoledronic Acid (1)  ·  cemiplimab (1)  ·  pembrolizumab (1)

Countries

United States (6)

Results publications

PMID 39863139